Myeloablative allogeneic versus autologous stem cell transplantation in adult patients with acute lymphoblastic leukemia in first remission: A prospective sibling donor versus no-donor comparison

Blood

Volumn 113, Issue 6, 2009, Pages 1375-1382

  Cornelissen, Jan J ^a,n   Van Der Holt, Bronno ^a,n   Verhoef, Gregor E G ^b,n   Van 't Veer, Mars B ^a,n   Van Oers, Marinus H J ^c,n   Schouten, Harry C ^d,n   Ossenkoppele, Gert ^c,n   Sonneveld, Pieter ^a,n   Maertens, Johan ^b,n   Van Marwijk Kooy, Marinus ^e,n   Schaafsma, Martijn R ^f,n   Wijermans, Pierre W ^g,n   Biesma, Douwe H ^h,n   Wittebol, Shulamit ^i,n   Voogt, Paul J ^j,n   Baars, Joke W ^k,n   Zachée, Pierre ^l,n   Verdonck, Leo F ^m,n   Löwenberg, Bob ^a,n   Dekker, Adriaan W ^m,n  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^c ACADEMIC MEDICAL CENTER   (Netherlands)

^d MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^e ISALA HOSPITAL   (Netherlands)

^f MEDISCH SPECTRUM TWENTE   (Netherlands)

^g HAGA HOSPITAL   (Netherlands)

^h ST ANTONIUS HOSPITAL   (Netherlands)

ⁱ MEANDER MEDICAL CENTER   (Netherlands)

^j Sittard Geleen Heerlen   (Netherlands)

^k NETHERLANDS CANCER INSTITUTE   (Netherlands)

^l ZiekenhuisNetwerk Antwerpen   (Belgium)

^m UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

ⁿ Dutch Belgian Cooperative Trial Group for Hematology Oncology (HOVON)   (Belgium)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER MORTALITY; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HIGH RISK POPULATION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; ORGAN DONOR; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT OUTCOME; ALLOTRANSPLANTATION; AUTOTRANSPLANTATION; COMPARATIVE STUDY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOSUPPRESSIVE TREATMENT; LIVING DONOR; METHODOLOGY; MIDDLE AGED; REMISSION; RISK FACTOR; SIBLING; TUMOR RECURRENCE;

ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIVING DONORS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROSPECTIVE STUDIES; REMISSION INDUCTION; RISK FACTORS; SIBLINGS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, AUTOLOGOUS; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 60849120787     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-07-168625     Document Type: Article

References (37)

1. Gökbuget N, Hoelzer D, Arnold R, et al. Treatment of adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am. 2004; 14:1307-1328.
2. Bassan R, Gatta G, Tondini C, et al. Adult acute lymphoblastic leukaemia. Crit Rev Oncol Hema-tol. 2004;50:223-261.
3. Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. HematologyAm Soc Hematol Educ Program. 2006;133-141.
4. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005;106:3760-3767.
5. Moorman AV, Harrison CJ, Buck GA, et al. For the Adult Leukaemia Working Party, Medical Research Council/National Cancer Research Institute. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109: 3189-3197.
6. Blume KG, Forman SJ, Snyder DS, et al. Allogeneic bone marrow transplantation for acute lymphoblastic leukemia during fist complete remission. Transplantation. 1987;43:389-392.
7. Zhang MJ, Hoelzer D, Horowitz M, et al. Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee. Ann Intern Med. 1995;123:428-431.
8. Sebban C, Lepage E, Vernant JP, et al. Allogeneic bone marrow transplantation in adult acute lymphoblastic leukemia in first complete remission: a comparative study. French Group of Therapy of Adult Acute Lymphoblastic Leukemia. J Clin Oncol. 1994;12:2580-2587.
9. Attal M, Blaise D, Marit G, et al. Consolidation treatment of adult acute lymphoblastic leukemia: a prospective, randomized trial comparing allogeneic versus autologous bone marrow transplantation and testing the impact of recombinant interleukin-2 after autologous bone marrow transplantation. BGMT Group. Blood. 1995;86: 1619-1628.
10. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia -results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357-2366.
11. Hunault M, Harousseau JL, Delain M, et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. Blood. 2004;104:3028-3037.
12. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004;22:4075-4086.
13. Cornelissen JJ, Carston M, Kollman C, et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. Blood. 2001;97:1572-1577.
14. Labar B, Suciu S, Zittoun R, et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia for patients < 50 years in first complete remission: results of the EORTC ALL-3 trial. Haematologica. 2004;89:809-817.
15. Ribera JM, Oriol A, Bethencourt C, et al on behalf of PETHEMA Group, Spain. Comparison of intensive chemotherapy, allogeneic or autologous stem cell transplantation as post-remission treatment for adult patients with high-risk acute lymphoblastic leukemia. Results of the PETHEMA ALL-93 trial. Haematologica. 2005;90:1346-1356.
16. Gray R, Wheatley K. How to avoid bias when comparing bone marrow transplantation with chemotherapy. Bone Marrow Transplant. 1991;3:9-12.
17. Wheatley K, Gray R. Commentary: Mendelian randomization - an update on its use to evaluate allogeneic stem cell transplantation in leukaemia. Int J Epidemiol. 2004;33:15-17.
18. Hahn T, Wall D, Camitta B, et al. The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of acute lymphoblastic leukemia in adults: an evidence-based review. Biol Blood Marrow Transplant. 2006;12:1-30.
19. Yanada M, Matsuo K, Suzuki T, et al. Allogeneic hematopoietic stem cell transplantation as part of postremission therapy improves survival for adult patients with high risk acute lymphoblastic leukemia: a meta-analysis. Cancer. 2006;106:2657-2663.
20. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukaemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the international ALL trial (MRC UKALL XII/ECOG E2993). Blood. 2008; 111:1827-1833.
21. Cornelissen JJ, van Putten WLJ, Verdonck LF, et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood. 2007;109: 3658-3666.
22. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9:1783-1786.
23. Assmann SF, Pocock SJ, Enos LE, et al. Subgroup analysis and other (mis)uses of baseline data in clinical trials. Lancet. 2000;355:1064-1069.
24. Lagakos SW. The challenge of subgroup analyses-reporting without distorting. New Eng J Med. 2006;354:1667-1669.
25. Fielding AK, Richards SM, Chopra R, et al. Outcome of 609 adults after relapse of acute lympho-blastic leukemia (ALL); an MRC UKALL12/ECOG 2993 study. Blood. 2007;109:944-950.
26. Gratwohl,A, Hermans J, Goldman JM, et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet. 1998;352:1087-1092.
27. Gratwohl A, Stern M, Apperley J, et al. Work Package Stem Cells of the European Leukemia Net. The EBMT risk score predicts outcome after allogeneic HSCT in all haematological disease categories and is independent of stem cell sources or conditioning intensity [abstract 105]. Bone Marrow Transplant. 2008;41:S39.
28. Sorror ML, Maris MB, Storb R, et al. Hematopoi-etic cell transplantation (HCT)-specific comorbid-ity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106:2912-2919.
29. Meijer E, Cornelissen JJ. Allogeneic stem cell transplantation in acute myeloid leukemia in first or subsequent remission: weighing prognostic markers predicting relapse and risk factors for non-relapse mortality. Semin Oncol. 2008;35:449-457.
30. Dhéedin N, Dombret H, Thomas X, et al. Autolo-gous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87, and -94 trials. Leukemia. 2006;20:336-344.
31. Gökbuget N,Arnold R, BöhmeA, et al. Improved outcome in high risk and very high risk ALL by risk adapted SCT and in standard risk ALL by intensive chemotherapy in 713 adult ALL patients treated according to the prospective GMALL study 07/2003. Blood (ASH Annual Meeting). 2007;110:12.
32. Van Dongen JJM, Seriu T, Panzer-Grümayer ER, et al. Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood. Lancet. 1998;352:1731-1738.
33. Van der Velden VHJ, Willemse MJ, van der Schoot CE, et al. Immunoglobulin κ deleting element rearrangements in precursor-B acute lymphoblastic leukemia are stable targets for detection of minimal residual disease by real-time quantitative PCR. Leukemia. 2002;16:928-936.
34. Van der Velden VHJ, Wijkhuijs JM, Jacobs DC, et al. T cell receptor γ gene rearrangements as targets for detection of minimal residual disease in acute lymphoblastic leukaemia by real-time quantitative PCR analysis. Leukemia. 2002;16:1372-1380.
35. Brüggemann M, Van der Velden VHJ, Raff T, et al. Rearranged T-cell receptor β genes represent powerful targets for quantification of minimal residual disease in childhood and adult T-cell acute lymphoblastic leukemia. Leukemia. 2004;18:709-719.
36. Brüggemann M, Raff T, FlohrT, et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood. 2006;107:1116-1123.
37. Raff T, Gökbuget N, Lüschen S, et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood. 2007;109: 910-915.